The data management of a phase III efficacy trial of an 11-valent pneumococcal conjugate vaccine and related satellite studies conducted in the Philippines

The data management of a phase III efficacy trial of an 11-valent pneumococcal conjugate vaccine and related satellite studies conducted in the Philippines

<p>Abstract</p> <p>Background</p> <p>A large phase III placebo-controlled, randomized efficacy trial of an investigational 11-valent pneumococcal conjugate vaccine against pneumonia in children less than 2 years of age was conducted in the Philippines from July 2000 to...

Full description

Bibliographic Details
Main Authors:	Sanvictores Diozele Hazel M, Lucero Marilla G, Nohynek Hanna, Tallo Veronica L, Tanskanen Antti, Nillos Leilani T, Williams Gail
Format:	Article
Language:	English
Published:	BMC 2012-06-01
Series:	BMC Research Notes
Online Access:	http://www.biomedcentral.com/1756-0500/5/274

Similar Items

Geographic Information System and tools of spatial analysis in a pneumococcal vaccine trial
by: Tanskanen Antti, et al.
Published: (2012-01-01)

Capture-recapture analysis of all-cause mortality data in Bohol, Philippines
by: Sanvictores Diozele, et al.
Published: (2011-04-01)

Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein – conjugated pneumococcal vaccine in Filipino infants
by: Käyhty Helena, et al.
Published: (2003-08-01)

Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children--a population-based study.
by: Jukka Jokinen, et al.
Published: (2015-01-01)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly.
by: Irina Kislaya, et al.
Published: (2019-01-01)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012-03-01)

Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study.
by: Arto A Palmu, et al.
Published: (2017-01-01)

Poor growth and pneumonia seasonality in infants in the Philippines: cohort and time series studies.
by: Stuart Paynter, et al.
Published: (2013-01-01)

Prevalence of pneumococcal nasopharyngeal colonization and serotypes circulating in Cameroonian children after the 13-valent pneumococcal conjugate vaccine introduction
by: John Njuma Libwea, et al.
Published: (2020-09-01)

Using mathematical transmission modelling to investigate drivers of respiratory syncytial virus seasonality in children in the Philippines.
by: Stuart Paynter, et al.
Published: (2014-01-01)

13-valent pneumococcal conjugate vaccine in Africa
by: Robert Cohen, et al.
Published: (2017-03-01)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
by: Anna M.M. van Deursen, et al.
Published: (2012-11-01)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019-03-01)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
by: George Gourzoulidis, et al.
Published: (2023-09-01)

The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
by: Adamu, AL, et al.
Published: (2023)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
by: Kristiana Alexandrova Nikolova, et al.
Published: (2021-10-01)

The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
by: Aishatu L. Adamu, et al.
Published: (2023-05-01)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
by: Hye-Young Kim, et al.
Published: (2021-03-01)

Decrease in pneumococcal co-colonization following vaccination with the seven-valent pneumococcal conjugate vaccine.
by: Carina Valente, et al.
Published: (2012-01-01)

Direct effect of 10-valent conjugate pneumococcal vaccination on pneumococcal carriage in children Brazil.
by: Ana Lucia Andrade, et al.
Published: (2014-01-01)

Invasive pneumococcal infection despite 7-valent conjugated vaccine
by: Sebastien Joye, et al.
Published: (2013-03-01)

Efficacy of 13-valent pneumococcal conjugate vaccine in healthcare workers
by: L A Shpagina, et al.
Published: (2018-11-01)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
by: Johnna Perdrizet, et al.
Published: (2021-04-01)

Predictors to parental knowledge about childhood immunisation/EPI vaccines in two health districts in Cameroon prior to the introduction of 13-valent Pneumococcal Conjugate Vaccines (PCV-13)
by: John Njuma Libwea, et al.
Published: (2014-03-01)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
by: Filippo Ansaldi, et al.
Published: (2020-01-01)

Mortality of Invasive Pneumococcal Disease following Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Greenland
by: Kristiana Alexandrova Nikolova, et al.
Published: (2024-02-01)

Pneumococcal meningitis: epidemiological profile pre‐ and post‐introduction of the pneumococcal 10‐valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015-03-01)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine
by: Sweta M. Patel, et al.
Published: (2022-01-01)

Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015-03-01)

Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia
by: Paul Turner, et al.
Published: (2015-11-01)

Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015-04-01)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
by: Earnshaw Stephanie R, et al.
Published: (2012-04-01)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
by: Germaine Hanquet, et al.
Published: (2022-01-01)

Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
by: Giske Biesbroek, et al.
Published: (2014-02-01)

Poor Potential Coverage for 7-Valent Pneumococcal Conjugate Vaccine, Malawi
by: Stephen B. Gordon, et al.
Published: (2003-06-01)

Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children
by: Corinne Levy, et al.
Published: (2021-08-01)

Experience with 13-valent conjugated pneumococcal vaccine in HIV-infected patients
by: A. V. Zhestkov, et al.
Published: (2020-12-01)

On the estimation of population cause-specific mortality fractions from in-hospital deaths
by: Gail M. Williams, et al.
Published: (2019-02-01)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
by: Mikkelsen Malene B, et al.
Published: (2023-08-01)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
by: Thundon Ngamprasertchai, et al.
Published: (2023-06-01)